Stay updated on Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision history updated to add v3.4.3 and remove v3.4.2.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1, with no substantive changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page revision updated from v3.4.0 to v3.4.1, a minor technical update that does not affect study content or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedGlossary toggle controls (Show glossary and Hide glossary) were added, and a capitalization change was made to the QC criteria metadata. Revision information now shows v3.4.0 instead of v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedRevision history updated: added Revision: v3.3.4 and removed Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check90 days agoChange DetectedAdded the Locations section with a Massachusetts site; removed the HHS Vulnerability Disclosure link and the previous Massachusetts Locations entry, and updated the revision to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page.